Comparative Selectivity and Specificity of the Proteasome Inhibitors BzLLLCOCHO, PS-341, and MG-132

Lisa J.A. Crawford,1 Brian Walker,2 Huib Ovaa,4,6 Dharminder Chauhan,5 Kenneth C. Anderson,5 Treen C.M. Morris,3 and Alexandra E. Irvine1

1Haematology, Centre for Cancer Research and Cell Biology and 2Pharmacy, Queen’s University Belfast; 3Department of Haematology, Belfast City Hospital, Belfast, United Kingdom; 4Pathology, Harvard Medical School; 5Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 6Division of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands

Abstract

The 26S proteasome is a multicatalytic protease responsible for regulated intracellular protein degradation. Its function is mediated by three main catalytic activities: (a) chymotrypsin-like (CT-L), (b) trypsin-like, and (c) peptidylglutamyl peptide hydrolysing (PGPH). Proteasome inhibition is an emerging therapy for many cancers and is a novel treatment for multiple myeloma. Here, we profile the contributions of the three catalytic activities in multiple myeloma cell lines and compare the specificity and cytotoxicity of the novel proteasome inhibitor BzLLLCOCHO and inhibitors PS-341 (Velcade, bortezomib) and MG-132. Using fluorogenic substrates and an active site-directed probe specific for proteasome catalytic subunits, we show differential subunit specificity for each of the inhibitors. Addition of BzLLLCOCHO strongly inhibited all three catalytic activities, treatment with PS-341 completely inhibited CT-L and PGPH activities, and treatment with MG-132 resulted in weak inhibition of the CT-L and PGPH activities. Multiple myeloma cells were more sensitive to induction of apoptosis by PS-341 and MG-132 than BzLLLCOCHO. This study emphasizes the need for further investigation of the effects of these compounds on gene and protein expression in the cell in order to allow for the development of more specific and targeted inhibitors. (Cancer Res 2006; 66(12): 6379-86)

Introduction

The ubiquitin proteasome pathway plays a central role in the regulation of protein degradation and maintenance of normal cell function (1–3). Proteins destined for proteolysis are tagged by the attachment of a polyubiquitin chain and subsequently degraded by the 26S proteasome. The 26S proteasome is a large multi-subunit complex composed of a central 20S catalytic core and two 19S regulatory caps. The 20S core particle is a cylindrical structure consisting of two outer heptamer rings of a subunits and two inner heptamer rings of β subunits. The three main catalytic activities of the proteasome, peptidylglutamyl peptide hydrolysing (PGPH), trypsin-like (T-L), and chymotrypsin-like (CT-L), are mediated by three distinct catalytic β1, β2, and β5 subunits, respectively (4). On exposure to IFN-γ, the activity of the 20S catalytic core can be modified. IFN-γ induces antigen-presenting cells to express β-type subunits β1, β2, and β5, which replace β1, β2, and β5, and the 19S caps are replaced by the 11S regulatory complex to form the immunoproteasome (5). The immunoproteasome is involved in the generation of antigenic peptides for presentation by major histocompatibility complex class 1 molecules (6).

Disregulation of the ubiquitin proteasome pathway has been implicated in the pathogenesis of many diseases, including cancer (7, 8). The proteasome has recently emerged as an attractive target for anticancer therapy. For example, clinical efficacy of proteasome inhibitors has been shown in multiple myeloma. PS-341 (Velcade, bortezomib), the first proteasome inhibitor to enter clinical trials, has been approved for the treatment of relapsed and refractory multiple myeloma (9) and is undergoing further clinical trials in previously untreated multiple myeloma, both as a single agent and in combination with conventional therapies (10, 11). The majority of proteasome inhibitors, including PS-341, are directed against CT-L activity, traditionally considered the rate-limiting step in protein degradation. Consequently, inhibitor potency has often only been measured against this activity. Despite much research into the substrate specificity of the individual catalytic activities, information about the involvement of the T-L and PGPH activities in the overall functioning of the complex is limited.

We have previously developed a method to extract proteasomes and to measure CT-L activity (12). In this study, we have extended this method to profile the relative contributions of the three catalytic activities of the proteasome in multiple myeloma cell lines. The specificity of the peptidyl α-keto aldehyde proteasome inhibitor BzLLLCOCHO (13) and proteasome inhibitors PS-341 and MG-132 on individual proteolytic activities was investigated using conventional fluorogenic substrates. In addition, we used a novel active site-directed probe to label catalytic subunits of both the constitutive and immunoproteasome (14). Differential subunit specificities were found for each of the inhibitors toward subunits of the constitutive and immunoproteasome. Furthermore, inhibition of proteasome activity did not correlate with induction of apoptosis.

Materials and Methods

Cells and culture conditions. Multiple myeloma cell lines U266 and OPM-2 and cervical carcinoma cell line HeLa were purchased from the European Collection of Cell Cultures (Salisbury, United Kingdom). KMS-11 and KMS-18 cells were obtained from Dr. Otsuki (Kawasaki Medical School, Okayama, Japan). PS-341-resistant and PS-341-sensitive lymphoma cell lines SU(DHL-4) and SU(DHL-6) were as previously described (13). All cell lines with the exception of HeLa were cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS and 10 μg/mL penicillin/streptomycin (Life Technologies, Inc., Paisley, United Kingdom). KMS-11 and KMS-18 cells were cultured in the absence of penicillin and streptomycin. HeLa cells were cultured in DMEM supplemented with 10% heat-inactivated FCS and 10 μg/mL penicillin-streptomycin.

References

Reagents. BzLLLCOCHO and the active site-directed probe (Dansylsulfonamidohexanoyl-L-Ahx-L3VS) were synthesized as described previously (14, 15). PS-341 was supplied by Millennium Pharmaceuticals (Cambridge, MA), and MG-132 was obtained from Sigma (Dorset, United Kingdom). Fluorogenic substrates Z-ARR-AMC, Z-LLE-AMC (Calbiochem, Nottingham, United Kingdom), and Succ-LLVY-AMC (Sigma) and caspase-8 and caspase-9 inhibitors (Sigma) were reconstituted in DMSO as a 10 mmol/L stock solution and stored at −20°C.

Proteasome extraction. Cells (1 × 10⁷) were harvested, resuspended in 1 mL ATP/DTT lysis buffer [10 mmol/L Tris-HCl (pH 7.8), 5 mmol/L ATP, 0.5 mmol/L DTT, 5 mmol/L MgCl₂], and incubated on ice for 10 minutes, followed by sonication for 15 seconds. The lysates were centrifuged at 4000 × g for 10 minutes at 4°C, and the resulting supernatant containing proteasomes was stable at −80°C with the addition of 20% glycerol for at least 1 month (12). Protein concentrations of the samples were measured using the Bradford dye binding assay (Perbio Science, Northumberland, United Kingdom) with bovine serum albumin as a standard.

Enzyme assay. The fluorogenic substrates Succ-LIVY-AMC, Z-ARR-AMC, and Z-LLE-AMC were used to measure CT-L, T-L, and PGPH proteasome activities, respectively. Assays were carried out in a 200 μL reaction volume containing 50 μg proteasome extract, 50 mmol/L EDTA, and 50 μmol/L fluorogenic substrate in ATP/DTT lysis buffer at 37°C. The rate of cleavage of fluorogenic peptide substrates was determined by monitoring the fluorescence of released aminomethylcoumarin using a Cytofluor Series 400 multiwell plate reader (Applied Biosystems, Warring- ton, United Kingdom) at an excitation wavelength of 395 nm and emission wavelength of 460 nm over a period of 35 minutes.

Western blotting. Multiple myeloma cells were cultured in the presence of each of the proteasome inhibitors as indicated, harvested, washed, and lysed in radioimmunoprecipitation assay lysis buffer (PBS, 1% Igepal CA-630, 0.1% SDS, 10% protease inhibitors). Equal amounts of protein were denatured by boiling in reducing sample buffer, separated by 4% to 12% SDSPAGE, and transferred onto polyvinylidene difluoride membranes. Immunoblotting was performed using an antibody against dansyl-sulfonamidohexanoyl (Molecular Probes, Leiden, the Netherlands), caspase-8, or caspase-9 (Calbiochem). Blots were scanned into the AutoChemi System (UVP, Cambridge, United Kingdom), and densitometry was performed using LabWorks 4.5 image acquisition and analysis software.

Cell viability and apoptosis assays. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer’s instructions (Sigma). Apoptosis was measured using two methods: Hoechst 33342/propidium iodide staining (Calbiochem) and ApoAlert Mitochondrial Membrane Sensor kit (Clontech United Kingdom, Hampshire, United Kingdom). Hoechst 33342 assesses membrane integrity, and propidium iodide assesses nuclear morphology. Cells were incubated with Hoechst 33342 (5 μg/mL) in culture medium for 20 minutes at 37°C, pelleted, and resuspended in 1 mL PBS containing 10 μL propidium iodide (10 mg/mL). Apoptosis was assessed using a fluorescent microscope with a 4,6-diamidino-2-phenylindole band-pass filter at ×40 magnification. ApoAlert detects changes in mitochondrial membrane potential using a cationic dye called Mitosensor. The kit was used according to the manufacturer’s instructions. Cells were viewed under a fluorescent microscope using a band-pass filter to detect fluorescein and rhodamine at ×40 magnification. For both methods, a minimum of 200 cells were scored for each sample.

Results
Profile of catalytic activities may be cell type dependent. Fluorogenic assays were used to investigate the level of the three

![Figure 1. Proteasome activity is higher in multiple myeloma cell lines than in lymphoma cell lines.](https://cancerres.aacrjournals.org/content/cancerres/66/12/6380/BF03303065/FULL/6380_BF03303065_HTML.png)
individual activities of the proteasome in multiple myeloma and lymphoma cell lines. Proteasome activity was measured by monitoring the release of the fluorophore aminomethylcoumarin (AMC) from peptide substrates specific for each activity (Suc-LLVY-AMC for CT-L, Z-ARR-AMC for T-L, and Z-LLE-AMC for PGPH). Activity was measured in four multiple myeloma cell lines (U266, OPM-2, KMS-11, and KMS-18), and the T-L and PGPH activities were found to account for a large proportion (88 ± 3%) of total proteasome activity (Fig. 1A). The rate of T-L activity was highest (50 ± 7%) followed by PGPH (35 ± 3%) and CT-L was the lowest (13 ± 3%). We next measured proteasome activity in the PS-341-resistant and PS-341-sensitive lymphoma cell lines (DHL-4 and DHL-6). The absolute CT-L activity in the lymphoma cell lines (4534 ± 685 AFU/50 μg) was comparable with that observed in KMS-18, U266, and OPM-2 lines (5625 ± 1310 AFU/50 μg); however, CT-L activity accounted for 48 ± 1% of total activity in lymphoma cell lines (Fig. 1B). These results suggest that the balance of catalytic activities may be dependent on cell type.

Subunit specificity of BzLLLCOCHO. The fluorogenic assay was initially used to evaluate the effect of the inhibitor BzLLLCOCHO on CT-L, T-L, and PGPH activities. Proteasome extracts were incubated with increasing concentrations (1, 5, and 10 μmol/L) of the inhibitor, and fluorescence was monitored using a fluorescent plate reader to determine activity. BzLLLCOCHO inhibited all three activities to a similar extent, with <75% of total activity achieved using 10 μmol/L BzLLLCOCHO (Fig. 2A). To determine whether BzLLLCOCHO is cell permeable, cells were incubated with 1, 5, and 10 μmol/L BzLLLCOCHO for up to 24 hours before extracting proteasome, and fluorescence was monitored. Maximal inhibition was reached within 3 hours, and incubation with 10 μmol/L BzLLLCOCHO inhibited total proteasome activity in U266 cells by an average of 91 ± 3%, indicating that the inhibitor is cell permeable (Fig. 2B).

To investigate the accuracy of the fluorogenic assay measurements, we used an active site-directed probe, DansylAhx3L3VS (15),...
to determine the subunit specificities of BzLLLCOCHO by its ability to compete for proteasome subunit labeling. DansylAhx3L3VS is a cell-permeable inhibitor that can covalently and irreversibly modify all of the exposed catalytic subunits of the proteasome. This probe has a dansyl-sulfonamidohexanoyl hapten tag attached to label and detect proteasome active sites of both constitutive proteasome and immunoproteasome. U266 cells were cultured in the presence of increasing concentrations of BzLLLCOCHO for 24 hours and then incubated with DansylAhx3L3VS to label remaining available subunits. Addition of BzLLLCOCHO reduced the ability of DansylAhx3L3VS to modify all proteasomal subunits of the constitutive and immunoproteasome in a dose-dependent manner. There was almost complete inhibition of the β1i and β2i subunits observed using 5 μmol/L BzLLLCOCHO, and labeling of the β2 band and β1, β5, and β5i bands was reduced by 77% and 82%, respectively, with 10 μmol/L BzLLLCOCHO (Fig. 2C). To further delineate the ability of BzLLLCOCHO to target the β1 and β5 subunits, HeLa cells expressing only the constitutive proteasome were incubated with 10 μmol/L BzLLLCOCHO and DansylAhx3L3VS. We found that labeling of the β2 (T-L) and β1 (PGPH) subunits was reduced by <80%, and the β5 (CT-L) subunit labeling was reduced by 46% (Fig. 2D). These results correspond well to our findings with the fluorogenic assay, showing that BzLLLCOCHO is a cell-permeable proteasome inhibitor targeting all three catalytic activities of the constitutive proteasome. In addition, we have found that BzLLLCOCHO is a strong inhibitor of all active subunits of the immunoproteasome.

Subunit specificity of the proteasome inhibitors PS-341 and MG-132. After characterizing BzLLLCOCHO, we compared its inhibitory profile to PS-341 (a dipeptide boronic acid analogue) and MG-132 (a peptide aldehyde), both of which are reported to target the CT-L activity. Proteasome activity was first measured using the fluorogenic assay following addition of increasing concentrations of PS-341 or MG-132 to U266 cell extracts. U266 cells were then incubated with either PS-341 or MG-132 for up to 24 hours before proteasome was extracted, and activity was measured to assess the activity of the inhibitors in whole cells. In cell extracts, PS-341 inhibited all three catalytic activities in a dose-dependent manner (Fig. 3A). Addition of 10 nmol/L PS-341 reduced CT-L activity by 74 ± 4%, T-L activity by 91 ± 3%, and PGPH activity by 50 ± 7%. Maximal inhibition was observed following preincubation with PS-341 for 6 to 12 hours, and there were
was a comparative reduction of all three activities with \( \geq 70\% \) of total proteasome activity achieved with 1 nmol/L PS-341 (Fig. 3B). Addition of MG-132 to cell extracts potently inhibited all catalytic activities with almost complete (>95%) inhibition achieved with 10 \( \mu \)mol/L MG-132 (Fig. 3C). However, when we measured proteasome activity in cells preincubated with MG-132, there was only 62 \( \pm \) 7% inhibition of total activity with 10 \( \mu \)mol/L MG-132 (Fig. 3D). The reason for this difference is unclear and may be due to cell permeability or less specificity of MG-132 for the proteasome in whole cells.

The active site-directed probe was also used to profile the subunit specificities of PS-341 and MG-132. U266 cells were cultured for 24 hours in the presence of 10 \( \mu \)mol/L BzLLLCOCHO, 5 nmol/L PS-341, or 1 \( \mu \)mol/L MG-132 and then incubated with DansylAhx3L3VS (Fig. 4). In comparison with previous observations (15, 16), treatment with PS-341 completely inhibited labeling of the \( \beta_1 \) (PGPH) and \( \beta_5 \) (CT-L) subunits along with immunoproteasome counterparts \( \beta_1i \) and \( \beta_5i \). In addition, there was an increase in labeling of the \( \beta_2 \) (T-L) and \( \beta_2i \) subunits, suggesting an increase in activity in these subunits. This is consistent with an increase in T-L activity on treatment with PS-341 as reported in other studies (16, 17). Treatment with MG-132 reduced labeling of all bands by \( \geq 53\% \), with the exception of \( \beta_2 \), which is increased 5-fold in response to this inhibitor. This is in keeping with findings by Berkers et al. (15) who also observed that MG-132 inhibited the \( \beta_2i \) subunit but not \( \beta_2 \), suggesting a difference in the active site chemistry between these two subunits. Looking at overall activity levels following treatment with the different inhibitors, BzLLLCOCHO reduces the labeling of all active subunits, whereas PS-341 and MG-132 seem to simultaneously activate one subunit while reducing the activity of others. This suggests that BzLLLCOCHO is the most effective of the three inhibitors in reducing total proteasome activity.

**Proteasome inhibitor-induced apoptosis.** The ability of the proteasome inhibitors to induce apoptosis in multiple myeloma cell lines (U266 and OPM-2) was evaluated using Mitosensor and Hoechst/propidium iodide staining. Cell lines were incubated with either 10 \( \mu \)mol/L BzLLLCOCHO, 5 nmol/L PS-341, or 1 \( \mu \)mol/L MG-132, and apoptosis was measured at 24-hour intervals. As seen in Fig. 5, cells were significantly more sensitive to the induction of apoptosis by PS-341 and MG-132 than BzLLLCOCHO. PS-341 has been shown previously to function through both caspase-8 and caspase-9 apoptotic pathways (18).
To determine the requirement for caspase-8-induced versus caspase-9-induced apoptosis with the different proteasome inhibitors, U266 cells were incubated with BzLLLCOCHO (10 μmol/L), PS-341 (5 nmol/L), or MG-132 (1 μmol/L) for 24 hours, harvested, and subjected to immunoblot analysis. As seen in Fig. 6A, treatment of U266 cells with BzLLLCOCHO and MG-132 also induce cleavage of caspase-8 and caspase-9 as is the case with PS-341. These results are confirmed by incubation of U266 cells with caspase-8 or caspase-9 inhibitors. Inhibition of either caspase-8 or caspase-9 leads to a significant decrease in cell death triggered by all three agents (Fig. 6B).

Discussion

Proteasome inhibition has shown great promise in the treatment of multiple myeloma, a malignancy that remains largely incurable with conventional therapies. There are three distinct proteolytic activities associated with the proteasome. The CT-L activity is the primary target of the majority of proteasome inhibitors. The individual roles of the three activities in the functioning of the proteasome are still under investigation, and there is conflicting evidence on how each activity contributes to the overall biological process. Although Jager et al. (19) suggested a hierarchy among the different sites, with the CT-L activity determining the rate of protein breakdown, they also indicated a degree of redundancy for all active subunits. Kisselev et al. (20) proposed the existence of mutual allosteric regulation between the active sites responsible for the CT-L and PGPH activities. More recently, it has been shown that the contributions of the different activities are dependent on the protein substrate, and Kisselev et al. (21) suggest that all three catalytic activities contribute significantly to protein degradation. In this study, we have profiled the relative contributions of the three activities in proteasome extracts from multiple myeloma and lymphoma cells. Although the rate of CT-L activity was highest in the lymphoma cell lines, the T-L and PGPH activities accounted for a large proportion of total activity in the multiple myeloma cell lines. This suggests that the balance of activities may be cell type dependent and that there may be increased therapeutic benefit by targeting all three catalytic subunits of the proteasome.

Fluorogenic peptide substrates have been widely used to measure the potency of proteasome inhibitors against the proteolytic activities. We have used this approach, along with a novel active site-directed probe, to characterize the subunit specificities of BzLLLCOCHO. Initial studies revealed our inhibitor to function as a slow-binding reversible inhibitor of the CT-L activity of the proteasome (14). In this study, we found

![Graphs](image_url)
BzLLLCOCHO to be a cell-permeable inhibitor that interacts with all subunits of both constitutive and immunoproteasome. Inhibition profiles of the well-characterized inhibitors PS-341 and MG-132, both of which were reported previously to be specifically targeted toward the β5 subunit (17, 22), were also investigated. There were differences in results obtained using fluorogenic assays compared with the active site-directed probe for these two inhibitors. These differences may, at least, in part, be due to the inability of fluorogenic assays to distinguish between the constitutive and immunoproteasome, underscoring the importance of additional tools for the characterization of subunit specificities of proteasome inhibitors. In agreement with Berkers et al. (15), Altun et al. (16) and Chauhan et al. (18) who also used active site-directed probes, we found that β5 was not the only subunit inhibited by PS-341 and MG-132. The kinetics of proteasome inhibition may be cell-type specific and occur in time and dose-dependent manner. Differential subunit specificities were observed for each of the inhibitors. Furthermore, all inhibitors were found to target immunoproteasome subunits, highlighting the need to take this proteasome species into account when evaluating the effects of proteasome inhibitors.

The majority of conventional therapies for multiple myeloma induce apoptosis through either death receptor pathway that is mediated by caspase-8 (e.g., γ radiation) or mitochondrial intrinsic pathway that is mediated by caspase-9 (e.g., dexamethasone; ref. 23). PS-341 has been reported to act through both caspase-8 and caspase-9 apoptotic signaling pathways (18, 24). The structurally distinct proteasome inhibitors BzLLLCOCHO and MG-132 were also shown to trigger apoptosis through both caspase-8 and caspase-9. When we compared the ability of the proteasome inhibitors to induce apoptosis in multiple myeloma cell lines, we found that induction of apoptosis by BzLLLCOCHO was significantly lower than with PS-341 and MG-132. In contrast, BzLLLCOCHO was shown to be the strongest inhibitor of proteasome activity both in fluorogenic assay measurements and using the activity-based probe. Many proteasome inhibitors do not specifically target the proteasome, and their biological effects may be partly explained by inhibition of other proteases. Cathepsin B and calpain 1 are additional targets of MG-132 (25). No additional targets for PS-341 have been reported to date. However, it is possible that proteasome inhibition is not the only requirement for PS-341-triggered or indeed BzLLLCOCHO-triggered apoptosis.

PS-341 is a first-in-class proteasome inhibitor and has validated the proteasome as a novel and legitimate target (26). Further investigation using genomic and proteomic approaches are required to delineate the effects of these inhibitors on gene and protein expression in the cell, providing the framework for the development of more specific and targeted inhibitors in the future.

Acknowledgments

Received 2/16/2006; accepted 3/24/2006.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


Comparative Selectivity and Specificity of the Proteasome Inhibitors BzLLLCOCHO, PS-341, and MG-132


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/12/6379

Cited articles
This article cites 26 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/12/6379.full.html#ref-list-1

Citing articles
This article has been cited by 18 HighWire-hosted articles. Access the articles at:
/content/66/12/6379.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.